Genmab A/S Q1 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jonathan Chang - LeeRink Partners - Analyst : This is you went. On for Jonathan. Thanks for taking our questions. So two from us. First one, can you help set expectations for the upcoming renal endometrial cancer data presentation at ESCO? And second, related to that, how should we be thinking about the commercial opportunity of renal as in endometrial cancer and how does that compare to the opportunity in ovarian cancer?

Question: Xian Deng - UBS - Analyst : Hey, thank you for taking my questions. To, at Kiley, please. The first one, so just wondering, so 190 million sales for this quarter, just wondering if you could give us a sense of a rough split between follicular lymphoma and DLBCL please. The reason I'm asking is that if I assume sort of 60 million AIDS, looking at the previous quarter for DLBCL, that means kind of 20 to 30 million or so for follicular lymphoma, that actually looks really good. Versus what Roche has achieved. So just wondering, any color on that, and what's the differentiating factor that the feedback there, particularly in follicular lymphoma, that would be great. The second question is, at Kingly second line plus fol follicular lymphoma, Give me now you plan to submit. In the first half of this year. So just wondering, appreciate you highlighted that the patient population here is about 9,000 patients, but just wondering what is your expected duration for this for this cohort place, because, 1 year or 2 year usage makes a huge difference in terms of sales?

Question: Yifeng Liu - HSBC - Analyst : Hello, thanks for taking my questions. I've got 21 is I was wondering if you could comment on the sort of environment for for BD now I've given all the macro volatility and and on tariffs and etc. Could you maybe provide some some update on the BD side and secondly it's on your R&D cost. And obviously a good result in first quarter, but you sort of reiterate our guidance.

Question: Vikram Purohit - Morgan Stanley - Analyst : Great, good afternoon. Thank you for taking our questions. We had to first on. The topic of your work in immunology. I know you have a partnership with organics focused on some early stage immunology work and you've also alluded to previously, I think, the potential for at Kinley in INI, so I just wanted to see if there's any updates on your thinking there for a future potential efforts in INI and how much of an internal priority that is for you right now, when you look at different opportunities across your pipeline? And then secondly, I was just curious on determining next steps for Gen 1,042. I think, your milestone calendar mentions you're going to be. Deciding on next steps there this year. Just wanted to see how you're thinking about that decision and kind of what determines the go no go there?

Question: Vikram Purohit - Morgan Stanley - Analyst : And also the path is that, of course, molecules this can originally developed for, oncology indications, can be excellent drugs, and other indications and INI. Is the area where antibody-based medicines have made an incredible difference to the treatment of patients, so we believe that we can be very strong there, but it's lagging behind the cancer focused opportunities. So I will stop there and then ask you to give a bit of call on 10:42 next steps. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 08, 2025 / 4:00PM, GMAB.CO - Q1 2025 Genmab A/S Earnings Call

Question: Asthika Goonewardene - Truist Securities - Analyst : Hi guys, thanks for taking the questions. So I got a couple, please. So on RAS, I want to just, close the loop on other tumor types beyond ovar and endometrial. There were expansion cohorts and lung and other tumor types which I thought would be fairly mature, this year for you to report data on, but you're not talking about them. Is that because they're still ongoing and the data is not ready yet, or are you deprioritizing development in those other tumor types outside of ovarian and endometrial? If the latter is it a full of the alpha expression issue. And then second, on Columbi, the, your competitor Columbi has an ad com coming up May 20th to discuss the SPLA for Starglow. It's a little odd given that Starle looks like a pretty successful trial with an OS benefit. So what do you think is the question that the FDA wants the panel to discuss? And do you anticipate the same might be, that FO might, face the same kind of question as well? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 08, 2025 / 4:00PM, GMAB.CO - Q1 2025 Genmab A/S Earnings Call

Question: Asthika Goonewardene - Truist Securities - Analyst : Thank you that. I think we'll leave it with that [Ashleya], but thanks for the question, sir.

Question: Matthew Phipps - William Blair - Analyst : Thanks for a question. Great to see [Kimly] move forward with the project front runner here and second line follicular. Wondering if you all are thinking about or have any agreements to use the project front runner and any other ongoing or planned phase 3 studies. I know the frontline follicular study also has a complete response endpoint. Perhaps that is maybe designed also for a potential project front runner path?

Question: Rajan Sharma - Goldman Sachs - Analyst : Hi, thanks for taking, the question. Just one from me and it's, maybe a bit of housekeeping. I just noticed on your, slides you're going to a core [DLBCL2] trial readout in in 2026, but clinicaltrials.gov still has the primary completion date of mid-27. Could you just help us reconcile that? Is it just a case of clinical trials.gov not being updated?